Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown

Asai, Tomohiro; Matsushita, Saori; Yonezawa, Sei; Yokota, Jun‐Ichi; Ishida, Tatsuhiro; Dewa, Takehisa; Kojima, Hiroshi; Nango, Mamoru; Oku, Naoto

doi:10.1016/j.bbrc.2008.01.074

Cited by 37 publications

(35 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Dicer, a miRNA processing machinery that has universal function in miRNA maturation, has been demonstrated to regulate cancer angiogenesis [28,29] . Data reported by Tomohiro et al have also indicated that AGO2 participated in controlling the growth of endothelial cells, thereby directly regulating angiogenesis [30] . In this study, another member of miRNA processing machinery-Ago2, has been revealed to indirectly regulate HCC angiogenesis through its regulatory effect on VEGF but not HIF1α (Supplementary Figure 1B).…”

Section: Discussionmentioning

confidence: 99%

Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma

Huang

et al. 2015

Acta Pharmacol Sin

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma

Huang

et al. 2015

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…For this purpose, we developed siRNA vectors modified with APRPG and formulated therapeutic siRNA candidates in these vectors. 23,24,29) Our results revealed that APRPG-modified vectors can be applicable to the systemic delivery of siRNA to angiogenic vessels.…”

Section: Prospects For Angiogenic Vessel-target-ing Ddsmentioning

confidence: 68%

Nanoparticle-Mediated Delivery of Anticancer Agents to Tumor Angiogenic Vessels

Asai

2012

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Nanoparticle-mediated drug delivery systems targeting tumor angiogenic vessels have been studied for antineovascular cancer therapy achieved by induction of apoptosis of angiogenic endothelial cells. Nanoparticles such as liposomes are considered to accumulate in tumors due to the enhanced permeability and retention effect. The delivery efficiency of this system appears to be affected by the density of tumor angiogenic vessels regardless of modification with tumor-targeting ligands on the surface of nanoparticles. It remains a challenging problem to deliver sufficient amounts of anticancer drugs to hypovascular tumors using nanoparticles. On the other hand, the strategy of angiogenic vessel-targeting is theoretically different from that of tumor cell-targeting since target angiogenic endothelial cells face the circulating blood. In addition, this strategy is expected to cause indirect tumor regression by disrupting angiogenic vessels. In this review, our recent studies are summarized to show the actual efficacy of angiogenic vessel-targeting delivery. We have developed various angiogenic vessel-targeted liposomes and evaluated them in experimental cancer models such as drug-resistant and hypovascular tumors. Our data indicate that increased apoptosis of angiogenic endothelial cells can be achieved by the targeted liposomes encapsulating cytotoxic drugs, resulting in enhanced anticancer effects. The advantages of angiogenic vessel-targeting are discussed based on our recent findings to provide an insight into why angiogenic vessels are a promising target for advanced cancer therapy.

show abstract

“…Western blotting was carried out as previously described [33]. Briefly, cells were seeded at a density of 250,000 cells/dish in a 10-cm dish.…”

Section: Western Blottingmentioning

confidence: 99%

Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma

Tagami

Suzuki

Hirose

et al. 2011

Drug Deliv. and Transl. Res.

Self Cite

View full text Add to dashboard Cite

Small interfering RNAs (siRNAs) are small RNA molecules that have a potent, sequence-specific gene silencing effect and therefore show promise for therapeutic use as molecular-targeted drugs for the treatment of various genetic diseases, including cancer. The aim of the present study was to evaluate whether Argonaute2 (Ago2) is a therapeutically effective target for siRNA-based cancer therapy. Ago2 is the key protein in mammalian RNAi and is also known as the only member of the Ago family that mediates the microRNA (miRNA)-dependent cleavage of targeted mRNAs. It is assumed that these unique properties of the Ago2 protein can play a central role in the regulation of the miRNA pathway and subsequent translational inhibition of miRNA-targeted mRNAs, including cell survival and cancer progression. To assess its therapeutic effect, siRNA against Ago2 (Ago2-siRNA) was transfected into HT1080 human fibrosarcoma cells, which are malignant cancer cells. Ago2 gene silencing resulted in the inhibition of cell growth and the induction of apoptosis and G0/G1 arrest in the cell cycle. In addition, Ago2 knockdown induced morphological changes and actin stress fiber formation in the cells. The results of a microarray study showed that Ago2 suppression stimulated several crucial genes related to apoptosis, the cell cycle, immune response, cell adhesion, metabolism, etc. Repeated intratumoral injection of Ago2-siRNA/cationic liposome complex induced tumor growth suppression in an HT1080 xenograft model. These results suggest that the suppression of the Ago2 gene may be useful for the inhibition of cancer progression and that Ago2 may be a desirable target for siRNA-based cancer therapy.

show abstract

Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown

Cited by 37 publications

References 17 publications

Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma

Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma

Nanoparticle-Mediated Delivery of Anticancer Agents to Tumor Angiogenic Vessels

Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma

Contact Info

Product

Resources

About